E
EonArk
AI biotechnology platform for longevity science research.
About EonArk
EonArk (无尽方舟) is a Shenzhen-based AI biotechnology startup building a longevity foundation model to reframe ageing as an engineering problem. The company learns conserved ageing signatures from cross-species, cross-organ single-cell data to locate regulatable network nodes, then validates AI-generated hypotheses back in the lab through a wet-dry-wet loop. Its H2P cross-species transfer-learning model uses single-cell transcriptomic data to identify anti-ageing drug targets with greater transfer potential, and methylation-based precision-health testing (biological age, genetic risk, long-term follow-up) serves as an early commercial entry point. The founding team spans AI, computational biology, gene editing and drug development, with members drawn from Oxford, the Francis Crick Institute, UC Berkeley, MIT and UCL.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2026
- Headquarters
- Shenzhen, China
- Open positions
- None listed
- Dealroom signal
- 16.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Genetics and genomics, Longevity
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning EonArk.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jul 2026 | $14M | $56M | Boyu Capital · Monolith Management | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases |
Graz, Austria | Operational | 1 | $7.8M | $17M |
 Senolytic TherapeuticsA discovery-stage biotech developing novel medicines that target senescent cells |
Barcelona, Spain | Closed | |||
 InSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases |
Cambridge, United States | Operational | |||
 C4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine |
Manchester, United Kingdom | Operational | |||
 PharnextDevelopment of treatments for severe neurological diseases |
Paris, France | Closed | |||
 NexRevo BioinformaticsDigital R&D ecosystems for life sciences innovation. |
London, United Kingdom | Operational | |||
 Interlit LLCBiotech & Life Sciences |
— | Operational | |||
 LunacellSingle-cell sequencing and analysis solutions for research |
Seongnam-si, South Korea | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Boyu Capital
Monolith Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EonArk on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EonArk’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.